A novel immuno-therapeutic platform in development: AbstimX™

In preclinical studies, scientists at Network Immunology Inc. have discovered how to treat and prevent the development of allergic disease and inflammatory colitis with Network Immunology's proprietary immuno-therapeutic technology and product in development,  AbstimX™.

Further, in one pilot study, a similar approach was administered and seen to be effective in preventing the development of inflammatory breast cancer in the mouse model.

Network Immunology welcomes collaborators and accredited investors to be a part of this venture.

For investment information, please contact George Hoffmann at george@networkimmunologyinc.com.


 


 

 

 

 

Corporate Updates

Captcha Image